Zya, a London food-ingredient startup, has raised a $15.2M Series A led by Astanor. The money will fund human studies and US launch prep for its sugar-to-fibre enzyme, Convero.
Key Takeaways
- Zya closed a $15.2M Series A (about £11.5M to £12M) on 16 November 2026, led by Astanor.
- Its Convero enzyme converts about 30% of sugar into prebiotic fibre only after a food is eaten.
- Valuation is undisclosed, and US commercial launch is targeted for the end of 2027.
Lead
Zya raised a $15.2M Series A on 16 November 2026, with Astanor leading. Ahren Innovation Capital, Red Bull Ventures, Zubi Capital, Phase Change and Meach Cove Capital also joined. The round is reported at between £11.5M and £12M depending on the outlet, and the company has not disclosed a valuation. The capital goes toward human studies, regulatory work and commercial partnerships ahead of a planned US launch with food manufacturers by the end of 2027.
What Does Zya Actually Sell?
Zya sells Convero, an enzyme made by precision fermentation in yeast and supplied to manufacturers as a dry powder. The enzyme, inulosucrase, stays inactive in low-moisture foods such as chocolate, cereal bars, biscuits and confectionery. Once the food reaches the aqueous environment of the stomach, it activates and converts roughly 30% of the sucrose into fructooligosaccharides (FOS), a prebiotic fibre, before the sugar is absorbed in the small intestine.
The pitch to brands is that the recipe does not change. Taste and texture stay put, and no alternative sweeteners are needed. The nutrition label would still show the same sugar content, so the benefit shows up in a front-of-pack claim, which Zya has proposed as "Now with Convero. Converts 30% of sugar into fiber after eating."
Who Is Behind the Company?
Zya was founded in 2018 by Oxford University biochemists Joshua Sauer (CEO) and Niels Leckie (CSO). Astanor backed the company with seed funding in 2022 and was among the investors in a 2023 pre-seed round alongside Better Ventures, Exor, Exerte Partners and Great Circle Ventures. The Series A therefore marks a lead investor doubling down rather than a new name taking the pen, which is a modest signal of conviction but says little about price.
Total funding to date has not been disclosed. Neither has the stake sold in this round, so the market has no way to judge what the Series A implies about the earlier rounds.
How Far Along Is the Science and Regulatory Work?
Zya has completed a 28-day rat feeding study and genotoxicity assessments, published in Toxicology Reports, along with in-vitro gut model work and preliminary pig studies. Human studies are the next step and are now funded. The company is pursuing a self-affirmed GRAS (generally recognised as safe) determination, expected by the end of 2026, followed by a formal submission to the US Food and Drug Administration.
Self-affirmed GRAS is faster than a full FDA notification, but it leaves the company dependent on customers' legal teams accepting the dossier. Zya says it is not pursuing reduced-calorie or blood glucose claims until it has more human data. That restraint limits the marketing upside in the near term, and it is the more defensible position.
What Is the Commercial Traction?
Zya reports more than 100 companies in its commercial pipeline and says it has completed feasibility projects with multinational food manufacturers. Several of those are progressing toward co-development agreements, though none has been named and none has been converted into a signed supply contract. Pipeline counts are cheap to assemble in ingredients, and the gap between a feasibility trial and a commercial listing is where many food-tech ingredients stall.
Manufacturing has been scaled to 10x pilot volume, with reproducibility shown across multiple runs. The company says the low dosage required keeps the economics workable, but it has given no cost figures. Because the enzyme is extracted without the engineered microbe, Zya says US bioengineered labelling would not apply.
Who Else Is Attacking Sugar Reduction?
Zya's approach sits against several rival ideas. ZBiotics uses a genetically engineered probiotic that produces a levansucrase enzyme, aimed at consumers. BioLumen has developed fibrous sponges that expand in the stomach to capture sugars. A Kraft Heinz and Wyss Institute project pairs an enzyme with a delivery system that protects it through the stomach and releases it in the small intestine.
Zya differs by supplying the enzyme itself, not a live organism, and by skipping any protective delivery system. As a business-to-business ingredient, it depends on large manufacturers adopting it across legacy brands. That model can scale quickly if a single anchor customer signs, and it can stall just as quickly if none does.
What Comes Next?
The first checkpoint is the self-affirmed GRAS determination, expected by the end of 2026. Human study results will then determine whether Zya can widen its claims beyond the fibre conversion itself. Low-moisture categories come first, and the company has flagged that processing steps which could inactivate the enzyme are a constraint it believes it can work around. Wet products such as beverages are outside the initial scope.
The decisive test is the end-of-2027 target for shipping the first products with US manufacturers. A Series A of this size gives the team a runway to reach that point, though not necessarily to commercial scale.
Outlook
Zya has funded the unglamorous middle of the path from lab to shelf: human data, regulatory filings and partner conversion. The technology is documented in peer-reviewed toxicology work, but the commercial case still rests on unnamed pilots and a pipeline figure. Signed co-development agreements and a clean GRAS outcome in the coming months will say more about the company than the size of the round.



